Due to a production error, the affiliation linked to Yan-Ping Chen and Hong-Dan Chen were incorrect. The correct author affiliations linked to the authors should be Shuang-Long Cai1†, Zhi-Hong Wang2†, Xiao-Geng Chen1, Lei Han1, Guo-Xian Gong3,Yan-Ping Chen4, Xiu-Quan Lin5, Ma Tao6, and Hong-Dan Chen7*.
There was also an error in Table 1 . The heading “Postoperative metastatic patients without BM (n=163)” should be “Postoperative metastatic patients with BM (n=51)”.
Table 1.
Risk factors of brain metastasis in Her2 positive postoperative breast cancer patients according to stratified variables: univariate analysis.
| Postoperative metastatic Postoperative metastatic | |||
|---|---|---|---|
| Variables | Patients without BM | Patients with BM | P value |
| (n=163) | (n=51) | ||
| No. (%) | No. (%) | ||
| Age at dx (years) | 49.09 ± 10.09 | 45.55 ± 10.09 | 0.03 |
| Age at diagnosis | 0.042 | ||
| ≤40 years | 32 (19.63) | 17 (33.33) | |
| >40 years | 131 (80.37) | 34 (66.67) | |
| Menopausal status at diagnosis | 0.077 | ||
| Premenopausal | 89 (54.60) | 35 (68.63) | |
| Postmenopausal | 74 (45.40) | 16 (31.37) | |
| Family history | 0.107 | ||
| No | 156 (95.71) | 45 (88.24) | |
| Yes | 7 (4.29) | 6 (11.76) | |
| Type of surgery | 0.616 | ||
| Radical surgery | 158 (96.93) | 48 (94.12) | |
| Breast conserving surgery | 5 (3.07) | 3 (5.88) | |
| Pathology type | 0.535 | ||
| Invasive ductal carcinoma | 122 (74.85) | 36 (70.59) | |
| Mixt | 38 (23.31) | 15 (29.41) | |
| Others | 3 (1.84) | 0 (0.00) | |
| Tumour grade | 0.471 | ||
| G1 | 3 (1.84) | 0 (0.00) | |
| G2 | 102 (62.58) | 27 (52.94) | |
| G3 | 52 (31.90) | 22 (43.14) | |
| Missing | 6 (3.68) | 2 (3.92) | |
| Tumour size staging | 0.322 | ||
| pT1 | 48 (29.45) | 15 (29.41) | |
| pT2 | 92 (56.44) | 24 (47.06) | |
| pT3-4 | 19 (11.66) | 11 (21.57) | |
| Missing | 4 (2.45) | 1 (1.96) | |
| Nodal staging | 0.221 | ||
| pN0 | 47 (28.83) | 21 (41.18) | |
| pN1 | 47 (28.83) | 8 (15.69) | |
| pN2 | 30 (18.40) | 11 (21.57) | |
| pN3 | 37 (22.70) | 10 (19.61) | |
| Missing | 2 (1.23) | 1 (1.96) | |
| Lymph nodes metastatic status | 0.091 | ||
| No metastasis | 47 (29.19) | 21 (42.00) | |
| Metastasis | 114 (70.81) | 29 (58.00) | |
| Estrogen receptor status | 0.082 | ||
| Negative | 70 (42.94) | 29 (56.86) | |
| Positive | 93 (57.06) | 22 (43.14) | |
| Progesterone receptor status | 0.069 | ||
| Negative | 85 (52.15) | 34 (66.67) | |
| Positive | 78 (47.85) | 17 (33.33) | |
| Time to first distant relapse | 0.139 | ||
| ≤2 years | 64 (39.26) | 26 (50.98) | |
| >2 years | 99 (60.74) | 25 (49.02) | |
| Type of chemotherapy | 0.496 | ||
| Anthracyclines | 9 (5.52) | 4 (7.84) | |
| Taxanes | 12 (7.36) | 5 (9.80) | |
| Anthracyclines+taxanes | 138 (84.66) | 40 (78.43) | |
| Other | 2 (1.23) | 0 (0.00) | |
| None | 2 (1.23) | 2 (3.92) | |
| Type of anti-HER2 treatment | 0.315 | ||
| Trastuzumab | 66 (40.49) | 20(39.22) | |
| Trastuzumab+pertuzumab | 0 (0.00) | 1(1.96) | |
| None | 97(59.51) | 30 (58.82) | |
| Adjuvant endocrine therapy | 0.248 | ||
| No | 84 (51.53) | 31 (60.78) | |
| Yes | 79 (48.47) | 20 (39.22) | |
| Adjuvant radiotherapy | 0.439 | ||
| No | 90 (55.21) | 25 (49.02) | |
| Yes | 73 (44.79) | 26 (50.98) | |
| First metastatic site | |||
| Lung metastasis | 0.027 | ||
| No | 105 (64.42) | 24 (47.06) | |
| Yes | 58 (35.58) | 27 (52.94) | |
| Liver metastasis | 0.429 | ||
| No | 127 (77.91) | 37 (72.55) | |
| Yes | 36 (22.09) | 14 (27.45) | |
| Bone metastasis | 0.135 | ||
| No | 120 (73.62) | 32 (62.75) | |
| Yes | 43 (26.38) | 19 (37.25) | |
| Metastatic cite in chest wall or regional lymph nodes | 0.407 | ||
| No | 66 (40.49) | 24 (47.06) | |
| Yes | 97 (59.51) | 27 (52.94) | |
BM, brain metastasis dx, diagnosis; Family history, HBOC related cancer history.
The corrected Table 1 and its caption “ Table 1 Risk factors of brain metastasis in Her2 positive postoperative breast cancer patients according to stratified variables: univariate analysis” appear below.
The publisher apologizes for these mistakes. The original version of this article has been updated.
Contributor Information
Collaborators: Frontiers Production Office